Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, and allogeneic stem cell transplantation in eligible patients, however, many patients will relapse after transplantation and many cannot withstand intensive chemotherapy. The identification of mutations such as FLT3-ITD, NMP1 and CEBPA has improved risk-stratification and treatment optimization, and novel post-transplant maintenance therapies are showing promise in improving outcomes for patients with AML.
In this podcast, Guillermo Sanz of the University Hospital La Fe, Valencia, Spain, Nico Gagelmann of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Mohamad Mohty of Saint-Antoine Hospital, Paris, France, and Farhad Ravandi, of the University of Texas MD Anderson Cancer Center, Houston, TX, share updates on their research in the field of AML which they presented at the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
The post Post-EBMT highlights in acute myeloid leukemia appeared first on VJHemOnc.
